Delving into the Latest Updates on GT-929 with Synapse

Overview

Basic Info

Drug Type

Molecular glue

Synonyms

GT 929, GT-929, GT929

Target

IKZF1 x IKZF3

Mechanism

IKZF1 inhibitors(DNA-binding protein Ikaros inhibitors), IKZF3 inhibitors(Zinc finger protein Aiolos inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Non-Hodgkin's lymphoma refractoryRecurrent Non-Hodgkin LymphomaMultiple Myeloma+ [2]

Inactive Indication-

Originator Organization

Biaoxin Biomedical Technology (Shanghai) Co., Ltd.

Active Organization

Biaoxin Biomedical Technology (Shanghai) Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

单药剂量递增阶段：主要目的：评价GT929用于治疗复发或难治性非霍奇金淋巴瘤（rrNHL）或复发或难治性多发性骨髓瘤（rrMM）的安全性、耐受性；探索剂量限制性毒性（DLT），确定最大耐受剂量（MTD）或II期研究推荐剂量（RP2D）；次要目的：评价GT929在rrNHL或rrMM患者中的药代动力学（PK）特征；评价GT929在rrNHL或rrMM中的初步疗效。剂量扩展阶段：主要目的：评价GT929在rrNHL或rrMM中的有效性；次要目的：评价GT929在rrNHL或rrMM中的安全性。

[Translation]

Single-drug dose escalation phase: Primary purpose: To evaluate the safety and tolerability of GT929 for the treatment of relapsed or refractory non-Hodgkin lymphoma (rrNHL) or relapsed or refractory multiple myeloma (rrMM); To explore dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) or recommended dose (RP2D) for Phase II studies; Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of GT929 in patients with rrNHL or rrMM; To evaluate the preliminary efficacy of GT929 in rrNHL or rrMM. Dose expansion phase: Primary purpose: To evaluate the efficacy of GT929 in rrNHL or rrMM; Secondary purpose: To evaluate the safety of GT929 in rrNHL or rrMM.

Start Date27 Feb 2024

Sponsor / Collaborator

Biaoxin Biomedical Technology (Shanghai) Co., Ltd.

100 Clinical Results associated with GT-929

Login to view more data

100 Translational Medicine associated with GT-929

Login to view more data

100 Patents (Medical) associated with GT-929

Login to view more data

100 Deals associated with GT-929

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Hodgkin's lymphoma refractory	Phase 2	CN	Biaoxin Biomedical Technology (Shanghai) Co., Ltd.	06 Mar 2024
Recurrent Non-Hodgkin Lymphoma	Phase 2	CN	Biaoxin Biomedical Technology (Shanghai) Co., Ltd.	06 Mar 2024
Multiple Myeloma	Phase 1	CN	Biaoxin Biomedical Technology (Shanghai) Co., Ltd.	27 Feb 2024
Hematologic Neoplasms	IND Approval	US	Biaoxin Biomedical Technology (Shanghai) Co., Ltd.	27 Oct 2023
Diffuse Large B-Cell Lymphoma	IND Approval	CN	Biaoxin Biomedical Technology (Shanghai) Co., Ltd.	24 Jul 2023